Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Accounts Payables (2016 - 2025)

Wave Life Sciences (WVE) has disclosed Accounts Payables for 11 consecutive years, with $15.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables fell 3.46% year-over-year to $15.7 million, compared with a TTM value of $15.7 million through Dec 2025, down 3.46%, and an annual FY2025 reading of $15.7 million, down 3.46% over the prior year.
  • Accounts Payables was $15.7 million for Q4 2025 at Wave Life Sciences, up from $14.5 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $18.1 million in Q2 2024 and bottomed at $7.3 million in Q4 2021.
  • Average Accounts Payables over 5 years is $12.9 million, with a median of $12.8 million recorded in 2023.
  • The sharpest move saw Accounts Payables crashed 47.22% in 2021, then skyrocketed 132.32% in 2022.
  • Year by year, Accounts Payables stood at $7.3 million in 2021, then surged by 132.32% to $16.9 million in 2022, then dropped by 24.1% to $12.8 million in 2023, then grew by 26.66% to $16.3 million in 2024, then dropped by 3.46% to $15.7 million in 2025.
  • Business Quant data shows Accounts Payables for WVE at $15.7 million in Q4 2025, $14.5 million in Q3 2025, and $14.7 million in Q2 2025.